国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (4): 312-314.doi: 10.3760/cma.j.issn.1673422X.2016.04.020

• 综述 • 上一篇    下一篇

EGFR-TKI在局部晚期非小细胞肺癌中的应用

吴霞, 冯国生   

  1. 530001 南宁,广西中医药大学研究生学院(吴霞);广西壮族自治区人民医院化疗一区(冯国生)
  • 出版日期:2016-04-08 发布日期:2016-03-02
  • 通讯作者: 冯国生,Email: fengguosheng88988@163.com E-mail:fengguosheng88988@163.com

Application of EGFR-TKI in locally advanced nonsmall cell lung cancer

Wu Xia, Feng Guosheng   

  1. Graduate School, Guangxi University of Chinese Medicine, Nanning 530001, China
  • Online:2016-04-08 Published:2016-03-02
  • Contact: Feng Guosheng E-mail:fengguosheng88988@163.com

摘要: 随着肺癌分子生物学研究的不断深入,小分子靶点类抗肿瘤药物取得了突破性的进展,表皮生长因子受体酪氨酸激酶抑制剂(EGFRTKI)是其中最受人关注的。多项研究证实了EGFRTKI具有放射增敏性。放疗单独联合EGFR-TKI可使身体状况差的患者生存获益,但仍不能忽视肺毒性。然而,EGFRTKI与放化疗联合能否使局部晚期NSCLC患者获益仍存在较大争议。

关键词: 癌, 非小细胞肺, 放射疗法, 表皮生长因子受体酪氨酸激酶抑制剂

Abstract: With the deepening of the lung cancer molecular biology research, small molecular targets antitumor drugs make breakthrough progress, the epidermal growth factor receptor tyrosine kinase inhibitor (EGFRTKI) is one of the most attention drug. A series studies show that EGFRTKI can enhance the antitumor activity of ionizing radiation. Therefore, EGFRTKI combined with radiotherapy alone for poorrisk patients appears survival benefit, but can′t ignore the lung toxicity. However, there is a big controversy that EGFRTKI combined with chemoradiotherapy for locally advanced NSCLC.

Key words: Carcinoma, nonsmallcell lung, Radiotherapy, Epidermal growth factor receptor tyrosine kinase inhibitor